Diagnosis of antiphospholipid syndrome.
Nat Clin Pract Rheumatol. 2005 Nov;1(1):40-6. – doi:10.1038/ncprheum0017
Antiphospholipid antibody tests: spreading the net.
Ann Rheum Dis 2005;64:1639–1643. doi: 10.1136/ard.2005.035824
The antiphospholipid syndrome.
Semin Nephrol. 2007 Jan;27(1):35-46. – doi:10.1016/j.semnephrol.2006.09.006
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review.
Blood, 2007 Nov 1;110(9):3122-7. – doi:10.1182/blood-2006-10-041814
Mechanisms of disease: antiphospholipid antibodies- from clinical association to pathologic mechanism.
Nat Clin Pract Rheumatol. 2008 Apr;4(4):192-9. – doi:10.1038/ncprheum0740
Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke.
Rheumatology, 2005;44:1161-5. – doi:10.1093/rheumatology/keh698
Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2- GPI) antibodies: importance of IgA isotype.
Clin Exp Immunol. 1999;117:574-9.
Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.
Ann Rheum Dis. 2003;62:1106-11. – doi: 10.1136/ard.62.11.1106
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost. 2006 Feb;4(2):295-306.
Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2- glycoprotein I and anti-phosphatidylserine/prothrombin antibodies – Co-existence of these antibodies enhances ADP-induced platelet activation in vitro.
Thromb Haemost. 2004 May;91(5):967-76. – doi:10.1160/TH03-10-0608
Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases.
J Thromb Haemost. 2007 Sep;5(9):1883-9.